ContraFect Corp.
(NASDAQ : CFRX)

( )
CFRX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
0.12%196.411.2%$567.51m
TSROTESARO, Inc.
0.08%74.3114.4%$551.02m
CELGCelgene Corporation
2.03%70.901.2%$541.17m
GILDGilead Sciences, Inc.
0.62%68.140.9%$521.04m
BIIBBiogen Inc.
0.88%322.611.3%$364.53m
ILMNIllumina, Inc.
2.44%336.923.5%$356.07m
REGNRegeneron Pharmaceuticals, Inc.
0.60%377.962.6%$267.70m
AAgilent Technologies, Inc.
0.99%71.751.5%$240.96m
VRTXVertex Pharmaceuticals Incorporated
1.28%175.451.9%$234.92m
ALXNAlexion Pharmaceuticals, Inc.
1.90%117.012.0%$146.65m
SRPTSarepta Therapeutics, Inc.
0.10%125.1315.4%$110.90m
INCYIncyte Corporation
3.16%67.672.5%$104.86m
EXASExact Sciences Corporation
3.27%71.7925.3%$97.81m
NKTRNektar Therapeutics
1.48%36.975.5%$91.00m
SGENSeattle Genetics, Inc.
1.66%61.956.6%$85.00m

Company Profile

ContraFect Corp. engages in discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases. Its pipeline consists of CF-301, a bacteriophage-derived lysin with potent activity against Staphylococcus aureus bloodstream infections; and CF-404, which composed of three fully human monoclonal antibodies designed to treat all seasonal strains of human influenza. The company was founded by Robert Nowinski on March 5, 2008 and is headquartered in Yonkers, NY.